The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis

BACKGROUND: Lung cancer is the leading cause of cancer‐related deaths worldwide and the prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or plus chemotherapy, both resulted in the survival benefit for patients with advanced non‐small‐cell lung cancer (NSCLC),...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chengdi, Qiao, Wenliang, Jiang, Yuting, Zhu, Min, Shao, Jun, Wang, Tao, Liu, Dan, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028135/
https://www.ncbi.nlm.nih.gov/pubmed/31693178
http://dx.doi.org/10.1002/jcp.29371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028135/
https://www.ncbi.nlm.nih.gov/pubmed/31693178
http://dx.doi.org/10.1002/jcp.29371

Ejemplares similares